We recently traveled to New York City for a State of the Science Summit on Multiple Myeloma. At the meeting, we spoke with the faculty of Mount Sinai to get their take on stem cell transplant, minimal residual disease, maintenance options, and treatment approaches for newly diagnosed myeloma. They also discussed outcomes for relapsed/refractory disease, novel agents in development, chimeric antigen receptor T-cell therapy, and immunotherapy.